Bioarctic AB, of Stockholm, said partner Abbvie Inc., of North Chicago, received U.S. Federal Trade Commission clearance to license Bioarctic's alpha-synuclein antibody portfolio for Parkinson's disease and other potential indications. (See BioWorld, Nov. 5, 2018.)